Metagenomi Presents Findings on Three New CRISPR-associated Gene Editing Systems and their Ability to Edit T-Cell and NK-Cell Genomes for Use in Cell Therapy
Retrieved on:
Friday, May 14, 2021
Research, Genetics, Clinical trials, Stem cells, Other Health, Biotechnology, General Health, Health, Science, Other Science, Branches of biology, Biology, Life sciences, Immune system, Biotechnology, Lymphocytes, Natural killer cell, Gene therapy, Emerging technologies, Chimeric antigen receptor T cell, MAGESTIC
Cost, Ph.D., Senior Director of Biology at Metagenomi, showed that the three CRISPR-associated gene editing systems produced extremely high-frequency gene editing in primary human T cells and NK cells.
Key Points:
- Cost, Ph.D., Senior Director of Biology at Metagenomi, showed that the three CRISPR-associated gene editing systems produced extremely high-frequency gene editing in primary human T cells and NK cells.
- None of the editing systems adversely affected cell viability.
- The precision and activity of the gene editing systems will enable efficient engineering and manufacture of allogenic cell therapies, including next-generation CAR Ts, CAR NKs, and TCR-based T cell therapies.
- Our goal is to revolutionize gene editing and unlock its power for the benefit of patients around the world.